Type 2 Diabetes

$150B+
Global Research Spending
100+
Years Since Insulin Discovery
0
FDA Cures Approved
Deferred
Cure Promise Status

A Century of Management

Insulin was discovered in 1921. Diabetes research has received $150 billion in global funding over the past 50 years. Treatments have improved dramatically. Patients live longer. Disease management has transformed medicine.

In 2024, there is still no cure. The promise of a cure has been deferred so many times that research now focuses on "remission" instead -- a semantic shift that conceals the absence of actual cure.

The Language Shift

In 2019, research began using the term "type 2 diabetes remission" instead of "cure." This is a meaningful distinction. Remission means the disease can return. Cure means it cannot. We stopped talking about cures.

Insulin Discovered 1921
Years Without Cure 103
New Drug Classes (2000--2024) 7
Remission Rates (Best Programs) 55--65%
Cure Rate 0%

The Promise Timeline

Type 2 diabetes research follows a familiar pattern: optimistic promises repeatedly deferred. The language changes. The underlying reality does not.

1921
Promise: Insulin discovered. Disease solved. Cure within reach.
1970
Reality: Insulin improved. Patients still have diabetes. Transplant complications high.
1990
Promise: Genomic revolution. Gene therapy will prevent disease. Cure by 2010.
2000
Reality: Genetics complex. Prevention difficult. New drugs improve management.
2010
Promise: Stem cell therapy. Pancreatic regeneration. Cure within 10 years.
2019
Reality: Language shifts to "remission" instead of "cure." Weight loss and intensive lifestyle management show 55--65% remission rates.
2024
Current: GLP-1 drugs (Ozempic, Mounjaro) show weight loss effects. Disease still incurable. Remission possible. Cure remains elusive.

What Works (And What Doesn't)

Type 2 diabetes research has produced real, measurable improvements in disease management. The honest assessment:

What Has Worked

Lifestyle Intervention: Weight loss of 5--10 kg leads to remission in 55--65% of early-stage type 2 diabetes patients (DiRECT trial, 2019). This is not a cure. Disease can return if weight returns.

Pharmacological Management: Seven new drug classes have been approved since 2000. GLP-1 receptor agonists show weight loss and cardiovascular benefits. Still not a cure. Still require ongoing treatment.

What Hasn't Worked

Pancreatic Transplant: Technically possible but high complication rates, immunosuppression required, limited availability. Not a scalable cure.

Gene Therapy: No approved gene therapy for type 2 diabetes. Clinical trials ongoing. No breakthroughs reported.

Stem Cell Regeneration: No approved stem cell treatment. Lab results promising. Human trials still early-stage.

The Remission Reality

When 55% of patients achieve remission through weight loss, that's real progress. But remission is not cure. 40--45% do not achieve remission. Those who do can relapse. The disease foundation remains.

Current Research Status

Type 2 diabetes research is active and well-funded. Progress on management is rapid. Progress on cure is static.

Active Clinical Trials 600+
FDA Approvals (2020--2024) 12+
GLP-1 Trial Efficacy (Weight Loss) 15--20% body weight
Cure-Focused Trials 0

Sources & Methodology

Data compiled from NIH, peer-reviewed sources, and public records.

Primary Sources

  • NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Funding Data
  • FDA Center for Drug Evaluation -- Type 2 Diabetes Drug Approvals (2020--2024)
  • The Lancet -- DiRECT Trial Results: Remission Rates (2019)
  • ClinicalTrials.gov -- Type 2 Diabetes Active Trials (600+ trials)
  • CDC -- Diabetes Statistics and Prevalence Data (2023)
  • American Diabetes Association -- State of Diabetes Science & Care (2024)
  • Nature Reviews Endocrinology -- Type 2 Diabetes Cure Research Review (2023)